In this article, we will discuss Aprepitant (Dosage Overview). So, let’s get started.
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Aprepitant, in combination with other antiemetic agents, is indicated for the:
• prevention of acute and delayed nausea and vomiting associated with initial and repeat
courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
• prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Prevention of Postoperative Nausea and Vomiting (PONV)
Aprepitant is indicated for the prevention of postoperative nausea and vomiting.
Limitations of Use
Aprepitant has not been studied for the treatment of established nausea and vomiting. Chronic continuous administration is not recommended.
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Capsules of Aprepitant are given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose of EMEND is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3.
Aprepitant may be taken with or without food.
EMEND (fosaprepitant dimeglumine) for Injection (115 mg) is a prodrug of aprepitant and may be substituted for oral EMEND (125 mg), 30 minutes prior to chemotherapy, on Day 1 only of the CINV regimen as an intravenous infusion administered over 15 minutes.